When administering an alpha-adrenergic blocker, the nurse should assess the patient for the development of what adverse effect?

Choice A rationale Alpha-adrenergic blockers primarily affect vascular tone by blocking alpha-1 adrenergic receptors, leading to vasodilation. While severe hypotension from these agents could theoretically compromise renal perfusion, renal failure is not a common or direct adverse effect. The primary concern is related to rapid changes in blood pressure, not a direct nephrotoxic effect on the kidneys themselves. Choice B rationale Alpha-adrenergic blockers cause vasodilation by inhibiting the sympathetic nervous system's vasoconstrictive effects on arterioles and veins. This leads to a decrease in peripheral vascular resistance and venous return. When the patient stands up, this vasodilation prevents the normal compensatory increase in blood pressure, resulting in a sudden drop in blood pressure and cerebral perfusion, clinically manifested as orthostatic hypotension. Choice C rationale Alpha-adrenergic blockers do not typically cause hyperglycemia. In fact, some alpha-1 antagonists have been shown to improve insulin sensitivity and glucose metabolism in patients with insulin resistance. The primary concern with this class of drugs is their effect on blood pressure, not their influence on glucose regulation, as their mechanism of action is distinct from hormonal pathways that regulate blood glucose levels. Choice D rationale Alpha-adrenergic blockers primarily act on the peripheral vascular system and have minimal to no direct effect on the respiratory drive centers in the brainstem. Respiratory depression is more commonly associated with central nervous system depressants, such as opioids or benzodiazepines, which act on different receptor systems. Therefore, this adverse effect is not a typical concern with alpha-adrenergic blocker administration.